California biopharmaceutical companies have laid off or projected layoffs for at least 1,176 employees this year, according to BioSpace tallies.
Over one in three of those 24 companies are pushing out at least half of their workforces, and two startups have shut down completely, BioSpace reported. Major industry players including AbbVie, BioMarin Pharmaceutical, Genentech, Gilead, and Takeda are among those implementing workforce reductions across the state.
Foster City-based Gilead is eliminating the highest number of personnel at 193 workers. That total includes 108 employees let go in June at the Redwood City headquarters of its wholly owned subsidiary Arcellx, according to data compiled by BioSpace.
While five major workforce reductions were disclosed in the fourth quarter, the wave of downsizing began in the first quarter of the year, as reported by BioSpace and pharmadog.xyz.
Nine Biotech Firms Cut Staff Drastically
Nine companies have eliminated most of their workforces, with San Diego startup f5 Therapeutics and Oakland biotech Tempero Bio shutting down entirely. f5 Therapeutics CEO Gary Choy announced the business closure on LinkedIn in March, noting that the preceding few years had proved brutal for early-stage biotechs, BioSpace reported.
The shutdown likely affected fewer than 10 employees based on the company’s LinkedIn page metrics at the time. f5 was developing molecular glues via its proprietary NExMod platform and had identified 11 potential targets before closing.
Tempero Bio shuttered in April following a serious adverse event in a Phase 2 trial of lead drug candidate TMP-301 for alcohol use disorder. Tempero CEO Paul Johnson did not disclose what happened with the study. The company maintained between two and 10 employees when it closed.
Subsequent cuts hit aTyr Pharma, which announced in August that it would lay off about 60% of its staff to focus resources on lead asset efzofitimod for interstitial lung disease. Arsenal Biosciences followed with a layoff of 99 employees—representing roughly 78% of its workforce—across its South San Francisco and Hayward locations, a company spokesperson told BioSpace.
Fourth-Quarter Workforce Reductions
Berkeley-based Caribou Biosciences announced in October that it would discontinue further development of its clinical-stage pipeline and implement a substantial workforce reduction amid a financing freeze in the CAR T space. Caribou filed a Worker Adjustment and Retraining Notification (WARN) Act notice to let go of 87 employees effective Dec. 7.
San Diego-based Artiva Biotherapeutics halted development of its lead candidate after two patient deaths and questions regarding clinical response durability. The company filed a WARN notice indicating a workforce reduction of 131 people effective Dec. 31.
LENZ Therapeutics announced a strategic reorganization in an SEC filing to prioritize resources on initiatives with high sales impact, cutting about 75% of its employees at its Solana Beach headquarters. President and CEO Eef Schimmelpennink departed as part of the transition, with a last day of Dec. 1.
Financial Report Cuts at Tempest and Calidi
Tempest Therapeutics cut three of its four full-time workers between June and September, amounting to a 75% reduction of its remaining staff, according to the Brisbane-based biotech’s latest quarterly financials. The company continues working with external consultants as it explores a merger or acquisition.
San Diego-based Calidi Biotherapeutics disclosed in an earnings report that it will let go of about 67% of its staff to extend its cash runway. The cuts will affect about 19 people across the company and its German subsidiary, StemVac GmbH.
| Company | Location | Reduction | Effective Date / Timing |
|---|---|---|---|
| Caribou Biosciences | Berkeley | 87 employees (approx. 90%) | Dec. 7, 2026 |
| Artiva Biotherapeutics | San Diego | 131 employees (94%) | Dec. 31, 2026 |
| LENZ Therapeutics | Solana Beach | Approx. 120 employees (75%) | By year’s end 2026 |
| Tempest Therapeutics | Brisbane | 3 full-time workers (75%) | June through September 2026 |
Frequently Asked Questions About California Biopharma Layoffs
Why are California biopharmaceutical companies making deep workforce reductions?
Companies are cutting staff due to clinical trial setbacks, financing freezes in specific sectors like CAR T therapies, and strategic shifts to preserve capital. For instance, Caribou Biosciences cited a financing freeze, while Artiva Biotherapeutics halted development following patient deaths in clinical trials.
How many biopharmaceutical employees have been affected in California so far?
BioSpace tallies show that 24 biopharmas have laid off or projected they will lay off at least 1,176 combined employees in the state this year. More than one in three of those companies are eliminating at least half of their workforces.
Which California biotech company is laying off the most workers?
Foster City-based Gilead is laying off the highest number of employees at 193 workers, which includes 108 people let go in June at the Redwood City headquarters of its subsidiary Arcellx.
BioSpace, launched online in 1995 as one of the first 50,000 websites worldwide, began in 1985 when Jennifer King founded the company to promote the emerging biotech industry through traditional publishing and its iconic Hotbed regional maps. The platform now draws over one million monthly visitors and hosts thousands of job listings, establishing it as the leading source for life sciences careers and news in the United States.
What happens to early-stage startups facing these industry pressures?
Some early-stage startups have closed entirely rather than restructuring. San Diego startup f5 Therapeutics and Oakland biotech Tempero Bio both wiped out their entire staffs through shutdowns after encountering funding challenges and clinical trial setbacks.
Worth a look